How, why, and when does primary biliary cirrhosis recur after liver transplantation?

Liver Transplantation

Volumn 13, Issue 9, 2007, Pages 1214-1216

  Williams, Roger ^a   Gershwin, M Eric ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; IMMUNOGLOBULIN A; MITOCHONDRION ANTIBODY; PREDNISOLONE; PYRUVATE DEHYDROGENASE COMPLEX; TACROLIMUS;

CLINICAL TRIAL; DISEASE SEVERITY; EDITORIAL; FOLLOW UP; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INCIDENCE; JAUNDICE; LIVER BIOPSY; LIVER TRANSPLANTATION; LOW DRUG DOSE; PATHOGENESIS; POSTOPERATIVE COMPLICATION; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PRURITUS; RISK ASSESSMENT; RISK FACTOR; SEX DETERMINATION; SJOEGREN SYNDROME; TREATMENT DURATION;

CHOLAGOGUES AND CHOLERETICS; HUMANS; LIVER CIRRHOSIS, BILIARY; LIVER TRANSPLANTATION; RECURRENCE; SURVIVORS; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 34648816688     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21143     Document Type: Editorial

References (24)

1. Neuberger J, Portmann B, Macdougall BR, Calne RY, Williams R. Recurrence of primary biliary cirrhosis after liver transplantation. N Engl J Med 1982;306:1-4.
2. Polson RJ, Portmann B, Neuberger J, Calne RY, Williams R. Evidence for disease recurrence after liver transplantation for primary biliary cirrhosis. Clinical and histologic follow-up studies. Gastroenterology 1989;97:715-725.
3. Starzl TE, Demetris AJ, Van Thiel D. Liver transplantation (2). N Engl J Med 1989;321:1092-1099.
4. Charatcharoenwitthaya P, Pimentel S, Talwalkar J, Enders F, Lindor K, Krom R, Wiesner R. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transplantation 2007;1236-1245.
5. Wong PY, Portmann B, O'Grady JG, Devlin JJ, Hegarty JE, Tan EC, Williams R. Recurrence of primary biliary cirrhosis after liver transplantation following FK506-based immunosuppression. J Hepatol 1993;17:284-287.
6. Neuberger J, Gunson B, Hubscher S, Nightingale P. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 2004;10:488-491.
7. Lombard M, Portmann B, Neuberger J, Williams R, Tygstrup N, Ranek L, et al. Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology 1993;104:519-526.
8. Wiesner RH, Ludig J, Lindor KD, Jorgensen PA, Baldus WP, Homburger HA, Dickson ER. A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. N Engl J Med 1990;322:1419-1424.
9. Shimoda S, Van de Water J, Ansari A, Nakamura M, Ishibashi H, Coppel RL, et al. Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis. J Clin Invest 1998;102:1831-1840.
10. Kita H, Lian ZX, Van de Water J, He XS, Matsumura S, Kaplan M, et al. Identification of HLA-A2-restricted CD8(+) cytotoxic T cell responses in primary biliary cirrhosis: T cell activation is augmented by immune complexes cross-presented by dendritic cells. J Exp Med 2002;195:113-123.
11. Kita H, Matsumura S, He XS, Ansail AA, Lian ZX, Van de Water J, et al. Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis. J Clin Invest 2002;109:1231-1240.
12. Van de Water J, Turchany J, Leung PS, Lake J, Munoz S, Surh CD, et al. Molecular mimicry in primary biliary cirrhosis. Evidence for biliary epithelial expression of a molecule cross-reactive with pyruvate dehydrogenase complex-E2. J Clin Invest 1993;91:2653-2664.
13. Migliaccio C, Nishio A, Van de Water J, Ansari AA, Leung PS, Nakanuma Y, et al. Monoclonal antibodies to mitochondrial E2 components define autoepitopes in primary biliary cirrhosis. J Immunol 1998;161:5157-5163.
14. Matsumura S, Van de Water J, Kita H, Coppel RL, Tsuji T, Yamomoto K, et al. Contribution to antimitochondrial antibody production: cleavage of pyruvate dehydrogenase complex-E2 by apoptosis-related proteases. Hepatology 2002;35:14-22.
15. Odin JA, Huebert RC, Casciola-Rosen L, LaRusso NF, Rosen A. Bcl-2-dependent oxidation of pyruvate dehydrogenase-E2, a primary biliary cirrhosis autoantigen, during apoptosis. J Clin Invest 2001;108:223-232.
16. He XS, Ansari AA, Ridgway WM, Coppel RL, Gershwin ME. New insights to the immunopathology and autoimmune responses in primary biliary cirrhosis. Cell Immunol 2006;239:1-13.
17. Aoki CA, Roifman CM, Lian ZX, Bowlus CL, Norman GL, Shoenfeld Y, et al. IL-2 receptor alpha deficiency and features of primary biliary cirrhosis. J Autoimmun 2006;27: 50-53.
18. Jones DE. Pathogenesis of primary biliary cirrhosis. J Hepatol 2003;39:639-648.
19. Neuberger J, Wallace L, Joplin R, Hubscher S. Hepatic distribution of E2 component of pyruvate dehydrogenase complex after transplantation. Hepatology 1995;22:798-801.
20. Van de Water J, Gerson LB, Ferrell LD, Lake JR, Coppel RL, Batts KP, et al. Immunohistochemical evidence of disease recurrence after liver transplantation for primary biliary cirrhosis. Hepatology 1996:24:1079-1084.
21. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006;130:715-720.
22. Jacob DA, Neumann UP, Bahra M, Klupp J, Puhl G, Neuhaus R, Langrehr JM. Long-term follow-up after recurrence of primary biliary cirrhosis after liver transplantation in 100 patients. Clin Transplant 2006;20:211-220.
23. Guy JE, Qian P, Lowell JA, Peters MG. Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant. Liver Transpl 2005;11:1252-1257.
24. Poupon R. Primary biliary cirrhosis: clinical aspects. In: Blumberg RS, Gangl A, Manns MP, Tilg H, Zeitz M, eds. Gut-Liver Interactions: Basic and Clinical Concepts. Springer: Dordrecht, The Netherlands. 2006;191-194.